Skip to main content
. 2016 Feb 16;7(12):14300–14309. doi: 10.18632/oncotarget.7426

Figure 1. RACK1 is overexpressed in imatinib-resistant GIST cells.

Figure 1

A. RACK1 mRNA expression in GIST-882R, GIST-T1R, and parental imatinib-sensitive cells was assessed by real-time PCR. B. Relative promoter activity of pGL3-GNB2L1-luc in GIST-882R, GIST-T1R, and parental imatinib-sensitive cells. C. RACK1 protein levels in GIST-882R, GIST-T1R, and parental imatinib-sensitive cells assessed by Western blots. D. Immunohistochemical analysis of RACK1 in tumor sections taken from representative GIST patients before (primary tumors) and after (relapse tumors) imatinib treatment (left panels). Scale bars: 50 μm. RACK1 expression in relapse GISTs after imatinib treatment was compared to matched primary tumors (right panel; n = 12). E. RACK1 protein levels in imatinib-resistant sublines of GIST-882 and GIST-T1 cells with or without MG132 treatment were determined by immunoblotting. β-actin was used as an internal control. Bars represent the mean of triplicate samples; error bars represent standard deviation. Data are representative of three independent experiments.